|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||93.05 / 128.39|
The longer we go without much progress, the more inclined players are to move to the sidelines.
Stocks fluctuate by late Thursday morning as a rally in Twitter shares fades.
This week's earnings announcements from Celgene and Biogen provided a contrast between volume- and price-driven revenue growth.
This is what we need to stop treading water and move this market to a tradable low.
Celgene (CELG) reported better-than-expected third-quarter results and raised its full-year outlook on Thursday morning.
Celgene Corporation (NASDAQ:CELG) reported net product sales of $2,969 million for the third quarter of 2016, a 28 percent increase from the same period in 2015.
U.S. stock futures turn higher; Qualcomm to buy NXP Semiconductors; Apple holds an event to reveal updates to the Mac.
Celgene (CELG) is scheduled to post 2016 third quarter earnings before Thursday's opening bell.
The lower the stock goes the better the opportunity to buy the stock with low risk.
The likely continuation of a split government should help the sector recover from its recent beat-down.
Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences in November where Celgene management will provide an overview of the Company.
Wall Street enters the thick of earnings reporting in week three of the season with heavyweights Apple and Alphabet on tap.
Jim Cramer says he's not a fan of HOT, likes MAR or EXPE better.
M&A may dominate headlines, but investors need to watch earnings as well, says Jim Cramer.
Gilead is under enormous pressure from investors to acquire companies or develop new drugs from its pipeline.
This sector is one of the few areas of the market where you'll find myriad compelling values.
Celgene announced today that adult patients in England and Wales with chronic plaque psoriasis will now have access to oral OTEZLA ® (apremilast) following a positive final appraisal determination from the National...
Celgene is not some dinky micro-cap biotech lacking the resources or knowledge to conduct a rigorous clinical trial, so omitting a placebo arm from the GED-0301 study is inexcusable.
Celgene's days of stellar growth will continue to stretch far into the future.
Celgene Corporation (NASDAQ: CELG) and Sage Bionetworks today announced a collaboration to develop an iPhone application utilizing the Apple ResearchKit framework to improve the understanding of the burden of disease for...
A close below $95 is likely to precipitate further short-term declines.
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that data from the open-label extension of the TOUCHSTONE phase 2 clinical trial of ozanimod in patients with...
Investors had reduced expectations for Celgene's experimental pill for Crohn's disease, which makes the new clinical data released Sunday night look all right, although doubts will persist.
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that data from a randomized, double-blind, multicenter, exploratory phase 1b study evaluating the...
Celgene Corporation (NASDAQ:CELG) today announced that findings from clinical trials of investigational compounds GED-0301 (mongersen), ozanimod and RPC4046 will be presented at the United European Gastroenterology (UEG)...
Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) today announced each company has entered into collaboration agreements with Abbott (NYSE: ABT), a leader in diagnostic technologies, to develop...
Don't focus on just one day of trading, Jim Cramer says.